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A prospective randomized, open-label trial comparing the safety and efficacy of dose sparing intradermal 2010/2011 trivalent 
influenza vaccine delivered by two different devices
Ivan FN Hung1, Yotam Levin2, Kelvin KW To1, Kwok-Hung Chan1, Patrick Li1, Clara Li1, Xu Ting1, Tin-Yan Wong1, Teresa Tong1, Kwok-Yung Yuen1.
State Key Laboratory for Emerging Infectious Diseases, Carol Yu’s Centre for Infection and Division of Infectious Diseases, the University of Hong Kong, Queen 
Mary Hospital, Hong Kong Special Administrative Region, China1 and NanoPass Technologies Ltd2, Israel.
Background 
We performed intradermal 2010/11 trivalent influenza vaccination (TIV) in adult subjects delivered by two different intradermal (ID) devices, using 20% and 
60% of the standard dose and compared the immunogenicity and safety with full dose intramuscular (IM) immunization.
Methods 
This is a prospective randomized trial conducted from December 2010 to March 2011, comprising chronically ill adults. Subjects were randomly assigned into 4 
groups. Groups ID3 and ID9 received a reduced dose ID TIV  (3µg and 9µg of hemagglutinin per strain respectively) delivered by MicronJet600TM. Group INT9 
received a reduced dose ID TIV (9µg) delivered by BD’s SoluviaTM device (Intanza®9). Control group IM15 received the full-dose IM TIV (15µg). We measured 
hemagglutination inhibition assay at baseline and day 21-post vaccination. 
Results
A total of 282 subjects enrolled of which 262 completed the study (ID3=63; ID9=68; INT9=65, IM15=66). Baseline characteristics for all groups were similar. 
The median age was 73.5 (68-78.5) years. At day 21, both seroconversion and seroprotection rates of the A/H1N1 strains by  hemagglutination-inhibition assay 
were significantly higher among the ID groups when compared with the IM control group [Figure 1 (p=0.017)] and seroprotection: [Figure 2 (p=0.024)]. The 
geometric mean titer (GMT) fold increase was also significantly  higher among the ID groups. [Figure 3]. Seroconversion rates of the H3N2 strain was 
significantly higher among the ID groups [Figure 1 (p=0.031). Non-inferiority of the intradermal vaccines was demonstrated for the rest of the tests. No serious 
adverse events related to vaccination were found. 
Conclusion
Immunogenicity of dose-sparing ID TIV was significantly better than the intramuscular vaccination of the H1N1 2009 component and partly also for the H3N2 
strain, despite significantly  lower doses used. All elderly and immunocompromised subjects indicated for the TIV should receive intradermal immunization in 
order to compensate for the reduced immunogenicity. Intradermal dose reduction is also important for cases of high demand during future pandemics.
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